OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
March 17, 2023
Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs utilizing the PEDAL platform.
Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.
The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.
March 16, 2023
Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.
27 drugs within Medicare will face penalties for having their prices raised faster than the rate of inflation.
March 15, 2023
Technological advances hold promise for mitigating human error in the pharmaceutical industry, especially in quality assurance/quality control, by reducing the incidence of, and risk associated with, mistakes.
A phase-appropriate analytical development strategy is crucial, especially for complex (formulated) drug substances.
The impact of the potential ban would have serious consequences for the availability of many drugs for European patients.
Organizations can better understand the maturity of AI-driven automation technology across their organization’s IT landscape through effective pharmacovigilance.